Ascendis Pharma (Nasdaq:ASND) - Aandelenkoers, Nieuws & Analyse

ASND Overzicht aandelen

Ascendis Pharma A/S, een biofarmaceutisch bedrijf, richt zich op de ontwikkeling van therapieën voor onvervulde medische behoeften.

Over het bedrijf

ASND fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

Verhandeld tegen 79.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 68.55% per jaar groeien

Risicoanalyse

Negatief eigen vermogen

Aandeelhouders zijn het afgelopen jaar verwaterd

Ascendis Pharma A/S Concurrenten

TG Therapeutics

NasdaqCM:TGTX

US$3.7b

Global Blood Therapeutics

NasdaqGS:GBT

US$4.6b

Rhythm Pharmaceuticals

NasdaqGM:RYTM

US$3.5b

Arcellx

NasdaqGS:ACLX

US$4.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Ascendis Pharma
Historische aandelenkoersen
Huidige aandelenkoers	US$129.36
52 Week Hoogtepunt	US$161.00
52 Week Laag	US$86.55
Bèta	0.64
11 maand verandering	-7.03%
3 maanden verandering	2.68%
1 Jaar Verandering	36.54%
33 jaar verandering	-15.48%
5 jaar verandering	14.42%
Verandering sinds IPO	586.99%

Recent nieuws en updates

Recent updates

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Oct 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Jun 27

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

May 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Feb 18

Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Sep 24

Ascendis Pharma: TransCon CNP Data Coming Q4

Sep 15

Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH

Aug 31

Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa

Aug 11

Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect

Aug 03

Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money

Jun 10

Rendement voor aandeelhouders

	ASND	US Biotechs	US Markt
7D	5.3%	1.6%	2.3%
1Y	36.5%	23.6%	35.1%

Rendement versus industrie: ASND overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 23.6 % opleverde.

Rendement versus markt: ASND overtrof de US markt, die het afgelopen jaar een rendement opleverde van 35.1 %.

Prijsvolatiliteit

Is ASND's price volatile compared to industry and market?
ASND volatility
ASND Average Weekly Movement	7.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ASND heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van ASND is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2006	879	Jan Mikkelsen	ascendispharma.com

Ascendis Pharma A/S, een biofarmaceutisch bedrijf, richt zich op de ontwikkeling van therapieën voor onvervulde medische behoeften. Het biedt SKYTROFA aan voor de behandeling van patiënten met een tekort aan groeihormoon (GHD). Het bedrijf ontwikkelt ook een pijplijn van drie onafhankelijke endocrinologie productkandidaten voor zeldzame ziekten in klinische ontwikkeling, en richt zich op het bevorderen van oncologie therapeutische kandidaten.

Ascendis Pharma A/S Samenvatting

Hoe verhouden de winst en inkomsten van Ascendis Pharma zich tot de beurswaarde?
ASND fundamentele statistieken
Marktkapitalisatie	US$7.66b
Inkomsten(TTM)	-US$525.46m
Inkomsten(TTM)	US$340.95m

22.7x

P/S-verhouding

-14.7x

Koers/Winstverhouding

Is ASND overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ASND resultatenrekening (TTM)
Inkomsten	€317.63m
Kosten van inkomsten	€45.88m
Brutowinst	€271.75m
Overige uitgaven	€761.27m
Inkomsten	-€489.52m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-8.19
Brutomarge	85.56%
Nettowinstmarge	-154.12%
Schuld/Eigen Vermogen Verhouding	-179.6%

Hoe presteerde ASND op de lange termijn?

Bekijk historische prestaties en vergelijking

ASND Overzicht aandelen

Beloningen

Risicoanalyse

Ascendis Pharma A/S Concurrenten

NasdaqCM:TGTX

US$3.7b

NasdaqGS:GBT

US$4.6b

NasdaqGM:RYTM

US$3.5b

NasdaqGS:ACLX

US$4.7b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

Consensus revenue estimates fall by 19%

Recent updates

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

Consensus revenue estimates fall by 19%

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Consensus EPS estimates fall by 13%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

Consensus estimates of losses per share improve by 17%

President notifies of intention to sell stock

President notifies of intention to sell stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Consensus revenue estimates increase by 12%

Ascendis Pharma's Ambitious Vision 2030

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

President notifies of intention to sell stock

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

New major risk - Negative shareholders equity

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Consensus revenue estimates decrease by 11%

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Key Executive notifies of intention to sell stock

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Consensus revenue estimates increase by 24%

Independent Chairman notifies of intention to sell stock

New major risk - Financial position

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023